Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29039196 | 1.00 | MEN1 (0.41) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| SCHEMBL31757881 | 1.00 | MEN1 (0.41) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| SCHEMBL7380569 | 1.00 | MEN1 (0.41) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| SCHEMBL7284071 | 1.00 | MEN1 (0.41) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| SCHEMBL10775306 | 1.00 | MEN1 (0.41) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL9872196 | 0.98 | MEN1 (0.39) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL7383292 | 0.98 | MEN1 (0.39) | MEN1BLMKMT2ASLC6A3SLC6A2 | |
| SCHEMBL19815556 | 0.94 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL19815510 | 0.94 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4967575 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-116234802-A | Quinoline CGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-0965585-A1 | Anti-amnesic thiazolidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-12-22 | — | — | EP | disclosed |
| EP-0537802-B1 | N-acylpyrrolidines, process for their preparation and their use for prevention and/or treatment of amnesia | ONO PHARMACEUTICAL CO (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-5545657-A | 1-ALKYLOYLPYRROLIDIN-2-YLOXOALKANOIC ACIDS AND DERIVATIVES; ANTIAMNESIA AGENTS; INHIBITORS OF PROLYL ENDOPEPTIDASE; SUPPRESSION OF NEUROTRANSMITTER METABOLISM | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-13 | — | — | US | disclosed |
| US-5411974-A | Thiazoline derivatives, treatment of amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5401760-A | Thiazoline derivative for treating amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0345428-B1 | Anti-amnesic pyrrolidine derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5212191-A | Thiazoline derivatives for treatment of amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| EP-0537802-A2 | N-acylpyrrolidines and N-acylthiazolidines, process for their preparation and their use for prevention and/or treatment of amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-21 | — | — | EP | disclosed |
| US-5053414-A | Thiazolidine derivatives, enzyme inhibitors; amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0345428-A1 | Anti-amnesic pyrrolidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MEN1 1514/4885BLM 38/4885KMT2A 4371/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | MEN1 1514/4885BLM 38/4885KMT2A 4371/4885 |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | MEN1 3217/4885BLM 3831/4885KMT2A 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.